Results 171 to 180 of about 33,352 (233)

Endothelin Receptor Antagonists [PDF]

open access: possiblePharmacology & Therapeutics, 2006
Endothelin receptor antagonists (ERAs) have been developed to block the effects of endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful vasoconstrictor with mitogenic or co-mitogenic properties, which acts through the stimulation of 2 subtypes of receptors [endothelin receptor subtype A (ETA) and endothelin receptor subtype
J D, Elliott   +4 more
openaire   +4 more sources

The endothelin system and endothelin receptor antagonists

Current Opinion in Nephrology & Hypertension, 2012
There is increasing evidence that endothelin receptor blockade and, in particular, ET(A) receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection.Recent clinical trials using ET(A) receptor blockade in treating proteinuria and chronic kidney disease as well as atherosclerosis show ...
Karin A M, Jandeleit-Dahm   +1 more
openaire   +2 more sources

Biotinylated endothelin as a probe for the endothelin receptor

Peptides, 1991
Biotinylated derivatives of endothelin (ET)-1 were prepared by chemical modification of ET-1 with sulfosuccinimidyl 6-(biotinamido) hexanoate. Two major biotinylated ET analogs were purified by reversed-phase high performance liquid chromatography.
I, Schvartz   +4 more
openaire   +2 more sources

Heterogeneity of Endothelin Receptor

Journal of Cardiovascular Pharmacology, 1991
The complex formed between endothelin (ET) and its binding protein was adequately stable to be separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) at low temperature. Cross-linking was not necessary. This simple method was applied for both qualitative (determination of molecular weight of ET binding protein) and ...
T, Takasuka   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy